// App-Quantinova.ai

1087.0 : Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis.

Researchers

Presenter

  • Karen A. Gelmon

Principal Investigators

  • Peter A. Fasching

  • Fergus Couch

  • Judith Balmana Gelpi

  • Suzette Delaloge

  • Intidhar Labidi-Galy

  • James Bennett

  • Susan McCutcheon

  • Sabine Ano

  • Joyce O'Shaughnessy

Medical Centers

  • Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

  • Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University...

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

  • Department of Medical Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institute of Oncology, Passeig de la Vall d'Hebron, Barcelona, Spain

  • Breast Cancer Unit, Department of Medical Oncology, Gustave Roussy, Villejuif, France

  • Department of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland

  • Baylor University Medical Center, Texas Oncology, Dallas, TX

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Human epidermal growth factor receptor 2

  • Hormone receptor

Drug/Treatment

  • Olaparib

  • taxane

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • NA

Study Id's

  • NCT03286842

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved